The Technology Development Board (TDB), under the Department of Science & Technology (DST), Government of India, has extended financial assistance to Vadodara-based medical device startup OrthoGraft Pvt. Ltd. to establish a production facility for advanced tissue-derived biological dressings aimed at wound-care applications.
The project, titled “Production Set-up for Advanced Tissue Derived Biological Dressings,” is focused on translating tissue-engineering research into commercially manufacturable products for the treatment of chronic wounds, diabetic foot ulcers, burns and other difficult-to-heal wounds.
OrthoGraft is a DPIIT-recognised medical device startup developing tissue substitutes for clinical reconstruction and functional repair. Its technology platform focuses on processing viable human tissue into shelf-stable tissue substitutes while retaining important biological and structural properties of native tissue that may support wound healing.
Tissue-processing technology at the centre of the project
The company's technology uses an advanced tissue-processing methodology designed to remove cellular components while preserving tissue quality and bioactive factors. The resulting biological dressings are being developed with improved tensile strength, high retention of bioactive components and a Moisture Vapour Transmission Rate (MVTR) comparable to commercially available moist wound dressings.
By combining tissue engineering, biomaterials science and specialised processing techniques, the project aims to transform suitable biomedical tissue material into high-value biological dressings for clinical wound-care applications.
TDB support to strengthen manufacturing capabilities
With financial assistance from TDB, OrthoGraft plans to strengthen its production infrastructure at the Savli Technology Business Incubator, Government of Gujarat, Vadodara, where it has leased a bio-incubation facility.
The location provides access to biotechnology research and development infrastructure supporting medical-device development and technology translation. The company has also obtained requisite CDSCO licences for manufacturing medical devices for testing purposes and is exploring collaborations with tertiary-care hospitals and medical institutions for further development and clinical translation.
OrthoGraft has developed multidisciplinary expertise in tissue processing and tissue substitutes and currently holds two granted US patents. The company is also working with institutions of national importance, including IIT Ropar, as well as multispecialty hospitals to advance its technology platform.
The startup has previously participated as an industry partner in Government of India-supported multi-institutional research, development and commercialization projects.
Focus on indigenous advanced wound-care technology
Speaking on the occasion, Shri Rajesh Kumar Pathak, Secretary, TDB, said that advanced biomaterials and tissue-engineered products represent an important frontier for India's medical technology ecosystem.
He noted that TDB's support is intended to help OrthoGraft translate its tissue-processing expertise into commercially manufacturable wound-care products, strengthening indigenous capabilities in advanced healthcare materials and creating opportunities for Indian innovations to compete in global markets.
The company said the financial assistance will enable it to establish dedicated production capabilities and accelerate the translation of its proprietary tissue-processing platform into clinically relevant products.
OrthoGraft aims to develop an indigenous portfolio of advanced tissue substitutes and expand the availability of biological wound-care solutions for patients with chronic and hard-to-heal wounds.
The initiative highlights the growing role of Indian startups in converting advances in tissue engineering and biomaterials into healthcare technologies with potential clinical and commercial applications.
